Meeting
2023 ASCO Annual Meeting
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
Authors
Amin Nassar
Yale Cancer Center, New Haven, CT
Amin Nassar , Elio Adib , Jamie Feng , Jacqueline V. Aredo , Kaushal Parikh , Jeremy Phillip Harris , Ana I. Velazquez Manana , Meera Vimala Ragavan , Jessica Jiyeong Lin , Zofia Piotrowska , Bailey Gleason Fitzgerald , Christian Grohé , Kamya Sankar , Joel W. Neal , Heather A. Wakelee , Frances A. Shepherd , Roy S. Herbst , Abdul Rafeh Naqash , Sarah B. Goldberg , So Yeon Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8567)
DOI
10.1200/JCO.2023.41.16_suppl.8567
Abstract #
8567
Poster Bd #
194
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2021 ASCO Quality Care Symposium
Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
First Author: Rahul Shenolikar
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura